Literature DB >> 22467243

Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer.

Elisabetta Munzone1, E Botteri, A Sciandivasci, G Curigliano, F Nolè, M Mastropasqua, N Rotmensz, M Colleoni, A Esposito, L Adamoli, A Luini, A Goldhirsch, G Viale.   

Abstract

The aim of this analysis was to investigate the usefulness of Ki-67 labeling index (LI) for the identification of different prognostic subgroups in primary node-negative, triple negative breast cancer (TNBC) patients. From January 1997 to December 2005, 1,053 patients operated for TNBC were identified through the institutional clinical database. The study was performed in accordance with REMARK criteria. The relationship between Ki-67LI and the risk of breast-related deaths was evaluated with a multivariable Cox regression model. Cubic splines were used to model Ki-67LI as a continuous variable. We selected 496 consecutive patients with node-negative TNBC. Median age was 52 years, median Ki-67LI 48% (range 4-95), and median follow up 6 years (range 0.5-13). Total deaths and deaths from BC were 52 (10.5%) and 38 (7.7%), respectively. Ki-67LI increased with decreasing age (P<0.01), increasing tumor size (P<0.01), and grade (P<0.01). When analyzing Ki-67LI as a continuous variable, the risk of death from BC increased steeply with increasing Ki-67LI up to about 35% and remained flat for higher values (adjusted effect of Ki-67 P=0.049; adjusted nonlinear effect P=0.021). Accordingly, when dividing patients into lower (≤35%) and higher (>35%) Ki-67LI subgroups, the 5-year cumulative incidence of breast-related deaths were 2.3 and 9.0%, respectively, with an adjusted HR(>35 vs ≤35) of 2.3 (95% CI 1.0-5.8, P=0.046). Within the group of patients with node-negative TNBC, Ki-67LI was associated with different prognoses subgroups. Ki-67LI might be useful in the design of trials of risk-adapted adjuvant therapies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22467243     DOI: 10.1007/s10549-012-2040-6

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  27 in total

1.  Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.

Authors:  Qi-Xing Tan; Qing-Hong Qin; Wei-Ping Yang; Qin-Guo Mo; Chang-Yuan Wei
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

2.  The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach.

Authors:  An Sen Tan; Joe Poe Sheng Yeong; Chi Peng Timothy Lai; Chong Hui Clara Ong; Bernett Lee; Jeffrey Chun Tatt Lim; Aye Aye Thike; Jabed Iqbal; Rebecca Alexandra Dent; Elaine Hsuen Lim; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2019-08-12       Impact factor: 4.064

3.  Prognostic value of Ki-67 according to age in patients with triple-negative breast cancer.

Authors:  V Zenzola; M A Cabezas-Quintario; M Arguelles; E Pérez-Fernández; Y Izarzugaza; A Correa; J García-Foncillas
Journal:  Clin Transl Oncol       Date:  2018-04-18       Impact factor: 3.405

4.  The search for optimal cutoff points for apoptosis and proliferation rate in prognostification of early stage breast cancer patients treated with anthracyclines in adjuvant settings.

Authors:  Beata Biesaga; Joanna Niemiec; Joanna Wysocka; Dorota Słonina; Marek Ziobro
Journal:  Tumour Biol       Date:  2015-12-19

5.  BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.

Authors:  Katerina Bouchalova; Marek Svoboda; Gvantsa Kharaishvili; Jana Vrbkova; Jan Bouchal; Radek Trojanec; Vladimira Koudelakova; Lenka Radova; Karel Cwiertka; Marian Hajduch; Zdenek Kolar
Journal:  Tumour Biol       Date:  2015-01-24

6.  Radiomics features on ultrasound imaging for the prediction of disease-free survival in triple negative breast cancer: a multi-institutional study.

Authors:  Feihong Yu; Jing Hang; Jing Deng; Bin Yang; Jianxiang Wang; Xinhua Ye; Yun Liu
Journal:  Br J Radiol       Date:  2021-09-03       Impact factor: 3.629

7.  Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series.

Authors:  Icro Meattini; Sara Cecchini; Cristina Muntoni; Vieri Scotti; Carla De Luca Cardillo; Monica Mangoni; Pierluigi Bonomo; Jacopo Nori; Donato Casella; Roberta Simoncini; Lorenzo Orzalesi; Simonetta Bianchi; Lorenzo Livi
Journal:  Med Oncol       Date:  2014-02-18       Impact factor: 3.064

8.  Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer-A Single Centre Prospective Observational Study.

Authors:  Chloe Constantinou; Savvas Papadopoulos; Eirini Karyda; Athanasios Alexopoulos; Niki Agnanti; Anna Batistatou; Haris Harisis
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

9.  KI-67 LI Expression in Triple-Negative Breast Cancer Patients and Its Significance.

Authors:  Maria A Arafah; Abderrahman Ouban; Omar Z Ameer; Ko Jin Quek
Journal:  Breast Cancer (Auckl)       Date:  2021-05-30

10.  The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.

Authors:  Carina Strand; Martin Bak; Signe Borgquist; Gunilla Chebil; Anna-Karin Falck; Marie-Louise Fjällskog; Dorthe Grabau; Ingrid Hedenfalk; Karin Jirström; Marie Klintman; Per Malmström; Hans Olsson; Lisa Rydén; Olle Stål; Pär-Ola Bendahl; Mårten Fernö
Journal:  Springerplus       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.